DNA Damage Response (DDR) Target Screening & Biomarker Profiling — Systematic Strategies for Precision Drug Discovery. Creative Biogene provides end-to-end DDR research solutions, integrating protein-level, biochemical, cellular, and molecular phenotyping assays with high-throughput screening and bioinformatics analysis. Our platform identifies critical DNA repair pathway targets and therapeutic vulnerabilities to accelerate drug development.
DNA damage response (DDR) pathways are essential for maintaining genomic stability, regulating cell survival, and influencing cancer drug resistance mechanisms. Major DDR pathways include base excision repair (BER), nucleotide excision repair (NER), homologous recombination (HR), and microhomology-mediated end-joining (MMEJ/TMEJ). Key targets such as WRN, PARP, POLQ, and p53 are involved in tumorigenesis, chemoresistance, and synthetic lethality strategies.
Drug discovery in DDR is challenging due to pathway complexity, cross-talk, tumor heterogeneity, and the need for precise target validation. Creative Biogene addresses these challenges by providing multi-level functional assays, high-throughput screening, and integrated bioinformatics, enabling systematic DDR target identification and mechanistic insights for novel therapeutic strategies.
Figure 1. DDR-related pathways and targets.
Helicase, ATPase, and exonuclease assays with MSI-H synthetic lethality validation. Supports inhibitor discovery and combination strategies.
PARylation activity, trapping assessment, and resistance mechanism analysis. Dual-target and combination screening available.
Dual-domain (polymerase + ATPase) functional assays, TMEJ pathway quantification, and HRD synthetic lethality validation.
Mutation classification, transcriptional activity, MDM2 interaction, and restoration/synthetic lethality screening.
We offer comprehensive biochemical and enzymatic profiling for critical DDR targets:
These assays are optimized for sensitivity, reproducibility, and compatibility with multi-compound screening campaigns.
Our cellular platform integrates customized cell panels covering MSI, high-MSI, and MSS tumor backgrounds:
This module supports high-content functional phenotyping, directly linking molecular mechanisms to cellular outcomes.
We utilize custom CRISPR-Cas9 knockout and RNAi screening to map drug-gene interactions systematically:
This platform enables prioritization of targets with therapeutic potential based on functional genomic evidence.
Our bioinformatics team provides end-to-end data processing, analysis, and interpretation:
This approach ensures that clients receive actionable knowledge beyond raw data, facilitating decision-making in preclinical development.
All workflows are automated and standardized for reproducibility and traceability.
CRISPR-Cas9 knockout of Fanconi anemia pathway genes FANCA and FANCD2 sensitized cancer cells to both crosslinking (cisplatin, mitomycin C) and methylating agents (temozolomide, MMS), demonstrating that FA pathway disruption compromises DNA damage repair across multiple lesion types. These results confirm the pathway's role in mediating cellular resistance and illustrate actionable DDR dependencies for target validation and therapy optimization.
Figure 2. Impact of FA pathway knockout on DNA damage sensitivity. Heatmaps and dose-response curves show that FANCA and FANCD2 knockout cells exhibit increased sensitivity to bifunctional alkylating agents and methylating drugs, reflecting the FA pathway's critical role in repair and synthetic lethality potential. (Heer et al., 2025)
Creative Biogene's DDR experts will respond within 24 hours to provide one-on-one consultation and design a fully customized DDR target screening and biomarker profiling solution to accelerate your precision drug discovery and translational research.
1. How is cell line selection optimized for DDR pathway screening?
We apply genomic characterization including MSI status, BRCA1/2 and PALB2 mutation profiling, and p53/ATM/ATR status to select or customize panels. Cell line panels can include 20–100 lines representing HRD-positive, MSI-high, and wild-type controls, ensuring biologically relevant screening for synthetic lethality or drug sensitivity studies.
2. What quality controls are implemented for biochemical assays?
Each enzymatic assay (WRN helicase, PARP, POLQ) includes positive and negative controls, replicate measurements (n ≥ 3), and internal calibration curves. ATPase and ADP-Glo readouts are validated for linearity (R² > 0.98) and signal-to-noise ratio (>5), ensuring quantitative reproducibility suitable for high-throughput screening.
3. How are CRISPR or RNAi functional screens standardized?
Our DDR-focused sgRNA libraries target >1,000 genes with 3–4 guides per gene. Transduction efficiency, editing validation (TIDE or NGS), and phenotypic readouts are quality-controlled. Z'-factor >0.5 is used to assess screen robustness before interpretation, aligning with published genome-wide CRISPR standards.
4. Can damaged or archived tissue samples be used for DDR biomarker profiling?
Yes. For FFPE or frozen tissue, we implement validated antigen retrieval and nucleic acid extraction protocols. γH2AX foci detection, RAD51 recruitment, and HRD scoring have been benchmarked against fresh tissue controls, with assay sensitivity sufficient to detect DNA damage events in ≤1,000 cells per section.
References:
Copyright © 2026 Creative Biogene. All rights reserved.